Innogenetics completes first US clinical trial on time
Safety and tolerability results of hepatitis B therapeutic vaccine phase I study
Innogenetics announced that it has successfully completed its first clinical study in the United States under Investigational New Drug status (IND).
In April 2004, Innogenetics took over sponsorship of a phase I safety and tolerability study under US IND for the hepatitis B therapeutic vaccine candidate, acquired from Genencor, based on Epimmune's polyepitope technology.
Final results of the phase I study showed that intramuscular injection with either a 0.4-mg or 4-mg dose of this DNA vaccine, administered every 4 weeks over a period of 12 weeks (a total of 4 doses), was safe and well tolerated in all healthy volunteers.
As planned, the next steps in the clinical evaluation program will be to deliver the hepatitis B polyepitope using a DNA vaccine and a viral vector in order to maximize the immune response.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.